[
    {
        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "T3N3TGK5kHu+neLOtZXrtOnpSw3grcBqr1rVJrHngOeardHubJl2iz+jiYJ8cgDP9/IiglORHW1fpPFWcjjz+QIwrLDtmxl9ORr30gi+JcjE+QHuVh/QNeZCFlfK/GrE32Gig9oSpEvtA1qVESS+9oyxeuts3EJg0u9U+qdz2KY="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-08-23T18:44:18.224+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_437",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_437"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB00468"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "\"Quinine sulfate is contraindicated in patients with the following:    Prolongation of QT interval ( 4 Glucose-6-phosphate dehydrogenase (G6PD) deficiency ( 4 Myasthenia gravis ( 4 Known hypersensitivity to quinine, mefloquine, or quinidine ( 4 Optic neuritis ( 4 Quinine sulfate is contraindicated in patients with the following:  * Prolonged QT interval. One case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged QT interval at baseline, who received quinine sulfate intravenously for  P. falciparum  [see WARNINGS AND PRECAUTIONS ( 5.3  * Glucose-6-phosphate dehydrogenase (G6PD) deficiency.  * Hemolysis can occur in patients with G6PD deficiency receiving quinine.  * Known hypersensitivity reactions to quinine.  * These include, but are not limited to, the following  [see WARNINGS AND PRECAUTIONS ( 5.6  * Thrombocytopenia  * Idiopathic thrombocytopenia purpura (ITP) and Thrombotic thrombocytopenic purpura (TTP)  * Hemolytic uremic syndrome (HUS)  * Blackwater fever (acute intravascular hemolysis, hemoglobinuria, and hemoglobinemia)  * Known hypersensitivity to mefloquine or quinidine: cross-sensitivity to quinine has been documented  [see WARNINGS AND PRECAUTIONS ( 5.6  * Myasthenia gravis. Quinine has neuromuscular blocking activity, and may exacerbate muscle weakness.  * Optic neuritis. Quinine may exacerbate active optic neuritis  [see ADVERSE REACTIONS ( 6\""
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/MedicalContraindication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB00468",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    }
]